Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prg25-02
- Development stage
- Preclinical
- Lead developer
- Tessellate BIO
- Modality
- Small Molecules
01
Overview
Prg25-02 is a preclinical-stage small molecule inhibitor being developed by Tessellate Bio in collaboration with Boehringer Ingelheim. It targets the Fanconi anemia group M protein (FANCM) complex, which is essential for the Alternative Lengthening of Telomeres (ALT) pathway. By inhibiting FANCM, Prg25-02 leverages synthetic lethality to selectively kill ALT-positive cancer cells—found in approximately 10-15% of cancers, including many sarcomas and brain tumors—while sparing healthy cells. The program includes the development of a companion C-Circle assay diagnostic to identify patients likely to benefit from the treatment.
- Other names
- ALT cancers program
02
Targets
FANCM (Fanconi anemia group M protein)
Beyond the preview
Go deeper on Prg25-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prg25-02.